ProfileGDS5678 / 1415976_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 94% 93% 93% 90% 93% 95% 94% 93% 92% 94% 94% 93% 93% 93% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.9788694
GSM967853U87-EV human glioblastoma xenograft - Control 27.9915393
GSM967854U87-EV human glioblastoma xenograft - Control 37.8404593
GSM967855U87-EV human glioblastoma xenograft - Control 47.4312390
GSM967856U87-EV human glioblastoma xenograft - Control 57.9758893
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3964495
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0579194
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.8861993
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.5891992
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.0259594
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.0866294
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.9469293
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.981693
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.9590193